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Biological drugs include a wide range of medicinal products 
created by biological instead of chemical processes. 
Biological drugs can consist of proteins, nucleic acids or 
complex combinations of substances, or may be living entities 
such as cells and tissues. They are isolated from natural 
sources or are produced by biotechnology methods. 
 
The aim of this study was: 
 To better know what are biopharmaceutical drugs.  
 To present a clinical project about the use of anti-TNFα 
molecules in rheumatoid arthritis and, 
 To give the role of biopharmaceuticals in the  future. 
Introduction 
Currently available classes of 
biopharmaceuticals 
The more common classes of biopharmaceuticals, currently on 
the market include hormones, cytokines, growth factor, 
antibodies, enzymes and vaccines. 
 
This drugs are considered outstanding compared to 
conventional drugs due to their  origin from a natural source. 
They don’t present the toxic effects that conventional could 
display. 
 
One of the main and most studied problems that present 
biopharmaceuticals is immunogenicity. In patients treated with 
immune-type products, such as monoclonal antibodies, these 
side effects occur frequently. 
 
Present of biopharmaceuticals 
Biopharmaceutical successful studies, conducted in Hospitals, 
have opened a new opportunity to control serious untreatable 
diseases.  
 
Biopharmaceuticals are going to be important players in the 
future of the Pharma Industry. 
Future of biopharmaceuticals 
Several Hospitals are already working with biopharmaceutical 
drugs. The Immunology Service of Hospital Clínic de 
Barcelona is driving a study with anti-TNFα molecules 
against rheumatoid arthritis. 
 
 
   Rheumatoid Arthritis 
 
 
 
 
 
 
Figure 1. Pathogenesis of rheumatoid arthritis 
Figure 2. Anti-TNFα molecules used by HCB 
Biological drugs have brought a revolution in the treatment of 
many serious diseases that had few therapeutic alternatives.  
 
Currently, there are more than thousand biological drugs in 
research. In the last decade they have been a third of the new 
drug approvals and it is estimated to be the world’s best selling 
drugs in 2016. 
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Anti-TNF α molecules 
Infliximab 
Chimeric monoclonal antibody against  TNFα used to treat 
autoimmune diseases. In rheumatoid arthritis, infliximab works  
by preventing TNF-α from binding to its  cellular receptor. 
 
Adalimunab 
Human monoclonal antibody against TNFα used to treat 
autoimmune diseases. It has been shown to reduce the signs and 
symptoms of moderate-to-severe rheumatoid arthritis in adults. 
 
Etanercept 
Fusion protein produced by recombinant DNA. Is a compound 
that treats autoimmune diseases acting as a TNF inhibitor. 
 
 
 
 
